Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion.

Elias J, van Dongen IM, Hoebers LP, Ouweneel DM, Claessen BEPM, Råmunddal T, Laanmets P, Eriksen E, Piek JJ, van der Schaaf RJ, Ioanes D, Nijveldt R, Tijssen JG, Henriques JPS, Hirsch A; EXPLORE investigators.

Eur Radiol. 2019 Jul 26. doi: 10.1007/s00330-019-06338-x. [Epub ahead of print]

PMID:
31350585
2.

Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial.

Kerkmeijer LSM, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout KE, Kraak RP, Weevers A, Piek JJ, de Winter RJ, Tijssen JGP, Henriques JPS, Wykrzykowska JJ, Ijsselmuiden A, Kauer F, Beijk MA, Vis M, Koch K.

EuroIntervention. 2019 May 23. pii: EIJ-D-19-00325. doi: 10.4244/EIJ-D-19-00325. [Epub ahead of print] No abstract available.

3.

Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial.

Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH, van der Schaaf RJ, Slagboom T, Vink MA.

JACC Cardiovasc Interv. 2019 May 16. pii: S1936-8798(19)30931-8. doi: 10.1016/j.jcin.2019.04.016. [Epub ahead of print]

PMID:
31126887
4.

Bioresorbable vascular scaffold versus Xience metallic stents: outcomes in the AIDA trial stratified by SYNTAX score.

Kraak RP, Tijssen RYG, van Dongen IM, Elias J, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers A, Tijssen JGP, Piek JJ, de Winter RJ, Henriques JPS, Wykrzykowska JJ; Collaborators.

EuroIntervention. 2019 May 7. pii: EIJ-D-18-00884. doi: 10.4244/EIJ-D-18-00884. [Epub ahead of print]

5.

Sex differences in characteristics and outcome in acute coronary syndrome patients in the Netherlands.

Ten Haaf ME, Bax M, Ten Berg JM, Brouwer J, Van't Hof AW, van der Schaaf RJ, Stella PR, Tjon Joe Gin RM, Tonino PA, de Vries AG, Zijlstra F, Boersma E, Appelman Y.

Neth Heart J. 2019 May;27(5):263-271. doi: 10.1007/s12471-019-1271-0.

6.

Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.

Tijssen RYG, van der Schaaf RJ, Kraak RP, Vink MA, Hofma SH, Arkenbout EK, Weevers APJD, Kerkmeijer LSM, Onuma Y, Serruys PW, Beijk MAM, Koch KT, Baan J Jr, Vis MM, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, Wykrzykowska JJ.

Catheter Cardiovasc Interv. 2019 Apr 9. doi: 10.1002/ccd.28193. [Epub ahead of print]

PMID:
30968559
7.

Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLORE-trial.

van Veelen A, van Dongen IM, Elias J, Råmunddal T, Eriksen E, van der Schaaf RJ, Claessen BEPM, Postema PG, Henriques JPS.

Catheter Cardiovasc Interv. 2019 Apr 9. doi: 10.1002/ccd.28282. [Epub ahead of print]

PMID:
30968546
8.

The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.

Tijssen RYG, Kerkmeijer LSM, Katagiri Y, Kraak RP, Takahashi K, Kogame N, Chichareon P, Modolo R, Asano T, Nassif M, Kalkman DN, Sotomi Y, Collet C, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Beijk MAM, Piek JJ, Tijssen JGP, Henriques JP, de Winter RJ, Onuma Y, Serruys PW, Wykrzykowska JJ.

Int J Cardiovasc Imaging. 2019 Jul;35(7):1189-1198. doi: 10.1007/s10554-019-01576-y. Epub 2019 Mar 25.

9.

Five-year results of the complete versus culprit vessel percutaneous coronary intervention in multivessel disease using drug-eluting stents II (CORRECT II) study: a prospective, randomised controlled trial.

Fagel ND, van Nooijen FC, Maarse M, Slagboom T, Herrman JP, van der Schaaf RJ, Amoroso G, Patterson MS, Laarman GJ, Suttorp MJ, Vink MA.

Neth Heart J. 2019 Jun;27(6):310-320. doi: 10.1007/s12471-019-1252-3.

10.

Safety and performance of a resorbable magnesium scaffold under real-world conditions: 12-month outcomes of the first 400 patients enrolled in the BIOSOLVE-IV registry.

Verheye S, Wlodarczak A, Montorsi P, Bennett J, Torzewski J, Haude M, Vrolix M, Buck T, Aminian A, van der Schaaf RJ, Nuruddin AA, Lee MKY.

EuroIntervention. 2019 Jan 22. pii: EIJ-D-18-01058. doi: 10.4244/EIJ-D-18-01058. [Epub ahead of print] No abstract available.

11.

Value of the SYNTAX Score in ST-Elevation Myocardial Infarction Patients With a Concomitant Chronic Total Coronary Occlusion(from the EXPLORE Trial).

van Dongen IM, Elias J, García-García HM, Hoebers LP, Ouweneel DM, Scheunhage EM, Delewi R, Råmunddal T, Eriksen E, Claessen BE, van der Schaaf RJ, Henriques JPS; EXPLORE investigators.

Am J Cardiol. 2019 Apr 1;123(7):1035-1043. doi: 10.1016/j.amjcard.2018.12.028. Epub 2019 Jan 4.

12.

Prehospital Prasugrel Versus Ticagrelor in Real-World Patients With ST-Elevation Myocardial Infarction Referred for Primary PCI: Procedural and 30-Day Outcomes.

Vos NS, Amoroso G, Vink MA, Maarse M, Adams R, Herrman JR, Patterson MS, van der Schaaf RJ, Slagboom T, de Winter RJ.

J Invasive Cardiol. 2018 Dec;30(12):431-436. Epub 2018 Oct 15.

13.

Angiographic and clinical outcomes of antegrade versus retrograde techniques for chronic total occlusion revascularizations: Insights from the PRISON IV trial.

Zivelonghi C, van Andel M, Venturi G, Amoroso G, Teeuwen K, Tijssen JGP, Tavella D, Ribichini F, Ten Berg JM, Resning BJ, Henriques JPS, Suttorp MJ, Agostoni P, Van der Schaaf RJ.

Catheter Cardiovasc Interv. 2019 Feb 1;93(2):E81-E89. doi: 10.1002/ccd.27795. Epub 2018 Oct 2.

PMID:
30280464
14.

Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.

Claessen BE, Henriques JPS, Vendrik J, Boerlage-van Dijk K, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, Piek JJ, Baan J Jr.

Catheter Cardiovasc Interv. 2019 Feb 1;93(2):216-221. doi: 10.1002/ccd.27814. Epub 2018 Sep 19.

PMID:
30232824
15.

The effect of revascularization of a chronic total coronary occlusion on electrocardiographic variables. A sub-study of the EXPLORE trial.

van Dongen IM, Kolk MZH, Elias J, Meijborg VMF, Coronel R, de Bakker JMT, Claessen BEPM, Delewi R, Ouweneel DM, Scheunhage EM, van der Schaaf RJ, Suttorp MJ, Bax M, Marques KM, Postema PG, Wilde AAM, Henriques JPS.

J Electrocardiol. 2018 Sep - Oct;51(5):906-912. doi: 10.1016/j.jelectrocard.2018.07.012. Epub 2018 Jul 19.

16.

Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial.

van Dongen IM, Elias J, van Houwelingen KG, Agostoni P, Claessen BEPM, Hoebers LP, Ouweneel DM, Scheunhage EM, Delewi R, Piek JJ, Råmunddal T, Laanmets P, Eriksen E, Bax M, Suttorp MJ, van der Schaaf RJ, Tijssen JGP, Henriques JPS.

Open Heart. 2018 Jul 16;5(2):e000810. doi: 10.1136/openhrt-2018-000810. eCollection 2018.

17.

Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI.

Tijssen RYG, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers A, Elias J, van Dongen IM, Koch KT, Baan J Jr, Vis M, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS, Wykrzykowska JJ.

EuroIntervention. 2018 Jul 20;14(4):e426-e433. doi: 10.4244/EIJ-D-18-00335.

18.

Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial.

Zivelonghi C, Teeuwen K, Agostoni P, van der Schaaf RJ, Ribichini F, Adriaenssens T, Kelder JC, Tijssen JGP, Henriques JPS, Suttorp MJ.

J Interv Cardiol. 2018 Oct;31(5):580-587. doi: 10.1111/joic.12516. Epub 2018 May 1.

PMID:
29717512
19.

Collateral Quality Decay Several Days After Primary Percutaneous Coronary Intervention: A Unique Observation From the EXPLORE Trial.

van Dongen IM, Elias J, van Houwelingen G, Agostoni P, Hoebers LP, Ouweneel DM, Delewi R, Claessen BEPM, van der Schaaf RJ, Henriques JPS; EXPLORE investigators.

JACC Cardiovasc Interv. 2018 Mar 12;11(5):511-512. doi: 10.1016/j.jcin.2017.11.033. No abstract available.

20.

Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction.

Elias J, van Dongen IM, Råmunddal T, Laanmets P, Eriksen E, Meuwissen M, Michels HR, Bax M, Ioanes D, Suttorp MJ, Strauss BH, Barbato E, Marques KM, Claessen BEPM, Hirsch A, van der Schaaf RJ, Tijssen JGP, Henriques JPS, Hoebers LP; EXPLORE investigators.

Heart. 2018 Sep;104(17):1432-1438. doi: 10.1136/heartjnl-2017-312698. Epub 2018 Feb 20.

PMID:
29463612
21.

A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.

Baan J Jr, Claessen BE, Dijk KB, Vendrik J, van der Schaaf RJ, Meuwissen M, van Royen N, Gosselink ATM, van Wely MH, Dirkali A, Arkenbout EK, de Winter RJ, Koch KT, Sjauw KD, Beijk MA, Vis MM, Wykrzykowska JJ, Piek JJ, Tijssen JGP, Henriques JPS.

JACC Cardiovasc Interv. 2018 Feb 12;11(3):275-283. doi: 10.1016/j.jcin.2017.10.024. Epub 2017 Nov 7.

22.

Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography.

Kraak RP, Kajita AH, Garcia-Garcia HM, Henriques JPS, Piek JJ, Arkenbout EK, van der Schaaf RJ, Tijssen JGP, de Winter RJ, Wykrzykowska JJ.

Catheter Cardiovasc Interv. 2018 Aug 1;92(2):E106-E114. doi: 10.1002/ccd.27475. Epub 2018 Jan 14.

PMID:
29332307
23.

Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial.

Elias J, van Dongen IM, Hoebers LP, Ouweneel DM, Claessen BEPM, Råmunddal T, Laanmets P, Eriksen E, van der Schaaf RJ, Ioanes D, Nijveldt R, Tijssen JG, Hirsch A, Henriques JPS; EXPLORE investigators.

J Cardiovasc Magn Reson. 2017 Jul 19;19(1):53. doi: 10.1186/s12968-017-0369-z.

24.

Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents.

Serruys PW, Katagiri Y, Sotomi Y, Zeng Y, Chevalier B, van der Schaaf RJ, Baumbach A, Smits P, van Mieghem NM, Bartorelli A, Barragan P, Gershlick A, Kornowski R, Macaya C, Ormiston J, Hill J, Lang IM, Egred M, Fajadet J, Lesiak M, Windecker S, Byrne RA, Räber L, van Geuns RJ, Mintz GS, Onuma Y.

J Am Coll Cardiol. 2017 Jul 4;70(1):60-74. doi: 10.1016/j.jacc.2017.05.028.

25.

Impact of Chronic Total Occlusion Location on LV Function in ST-Segment Elevation Myocardial Infarction Patients.

Elias J, Hoebers LP, van Dongen IM, Claessen BEPM, van der Schaaf RJ, Tijssen JG, Hirsch A, Henriques JPS; EXPLORE Investigators.

J Am Coll Cardiol. 2017 May 9;69(18):2347-2348. doi: 10.1016/j.jacc.2017.02.054. No abstract available.

26.

Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.

Wykrzykowska JJ, Kraak RP, Hofma SH, van der Schaaf RJ, Arkenbout EK, IJsselmuiden AJ, Elias J, van Dongen IM, Tijssen RYG, Koch KT, Baan J Jr, Vis MM, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS; AIDA Investigators.

N Engl J Med. 2017 Jun 15;376(24):2319-2328. doi: 10.1056/NEJMoa1614954. Epub 2017 Mar 29.

27.

Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.

Teeuwen K, van der Schaaf RJ, Adriaenssens T, Koolen JJ, Smits PC, Henriques JP, Vermeersch PH, Tjon Joe Gin RM, Schölzel BE, Kelder JC, Tijssen JG, Agostoni P, Suttorp MJ.

JACC Cardiovasc Interv. 2017 Jan 23;10(2):133-143. doi: 10.1016/j.jcin.2016.10.017.

28.

Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial.

Henriques JP, Hoebers LP, Råmunddal T, Laanmets P, Eriksen E, Bax M, Ioanes D, Suttorp MJ, Strauss BH, Barbato E, Nijveldt R, van Rossum AC, Marques KM, Elias J, van Dongen IM, Claessen BE, Tijssen JG, van der Schaaf RJ; EXPLORE Trial Investigators.

J Am Coll Cardiol. 2016 Oct 11;68(15):1622-1632. doi: 10.1016/j.jacc.2016.07.744.

29.

Impact of percutaneous coronary intervention timing on 5-year outcome in patients with non-ST-segment elevation acute coronary syndromes. The 'wait a day' approach might be safer.

Oosterwerff EF, Fagel ND, Slagboom T, Tijssen JG, Herrman JP, Smits PC, Suttorp MJ, Ronner E, Laarman GJ, Patterson MS, Amoroso G, Vink MA, van der Schaaf RJ, Verheugt FW, Riezebos RK.

Neth Heart J. 2016 Mar;24(3):173-80. doi: 10.1007/s12471-016-0803-0.

30.

Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial.

Ouweneel DM, Engstrom AE, Sjauw KD, Hirsch A, Hill JM, Gockel B, Tuseth V, van der Schaaf RJ, Henriques JP.

Int J Cardiol. 2016 Jan 1;202:894-6. doi: 10.1016/j.ijcard.2015.10.063. Epub 2015 Oct 9. No abstract available.

PMID:
26476989
31.

REVascularization with paclitaxEL-coated balloon angioplasty versus drug-eluting stenting in acute myocardial infarcTION-A randomized controlled trial: Rationale and design of the REVELATION trial.

Vos NS, van der Schaaf RJ, Amoroso G, Herrman JP, Patterson MS, Slagboom T, Vink MA.

Catheter Cardiovasc Interv. 2016 Jun;87(7):1213-21. doi: 10.1002/ccd.26241. Epub 2015 Sep 15.

PMID:
26370515
32.

EAPCI Focus on the Interventional Cardiology Working Group of The Netherlands Society of Cardiology (NVVC).

van der Schaaf RJ.

EuroIntervention. 2015 Mar;10(11):2 p following 1259. No abstract available.

PMID:
25973458
33.

A prospective, postmarket study with the Mguard Prime Embolic Protection Stent in ST-segment elevation myocardial infarction: the International MGuard Prime Observational Study (IMOS Prime).

Amoroso G, Vos NS, Van der Heyden JA, van der Schaaf RJ, Patterson MS, Vink MA, Herrman JP, Slagboom T.

Catheter Cardiovasc Interv. 2015 Oct;86 Suppl 1:S28-33. doi: 10.1002/ccd.25914. Epub 2015 Mar 24.

PMID:
25754236
34.

First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients.

Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski L, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H.

Open Heart. 2014 Aug 21;1(1):e000064. doi: 10.1136/openhrt-2014-000064. eCollection 2014.

35.

Subepicardial haematoma, a rare and potentially lethal complication of CTO-PCI: case of an exceptional recovery after conservative management.

de Vos AM, van der Schaaf RJ.

BMJ Case Rep. 2014 Oct 9;2014. pii: bcr2014204767. doi: 10.1136/bcr-2014-204767.

36.

Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study.

Vos NS, Dirksen MT, Vink MA, van Nooijen FC, Amoroso G, Herrman JP, Kiemeneij F, Patterson MS, Slagboom T, van der Schaaf RJ.

EuroIntervention. 2014 Sep;10(5):584-90. doi: 10.4244/EIJV10I5A101.

37.

A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.

Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y.

Lancet. 2015 Jan 3;385(9962):43-54. doi: 10.1016/S0140-6736(14)61455-0. Epub 2014 Sep 14.

PMID:
25230593
38.

Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.

Teeuwen K, Van den Branden BJ, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ.

EuroIntervention. 2015 Mar;10(11):1272-5. doi: 10.4244/EIJY14M08_07.

39.

Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions.

Van den Branden BJ, Teeuwen K, Koolen JJ, van der Schaaf RJ, Henriques JP, Tijssen JG, Kelder JC, Vermeersch PH, Rensing BJ, Suttorp MJ.

EuroIntervention. 2013 Nov;9(7):841-53. doi: 10.4244/EIJV9I7A138.

40.

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.

Teeuwen K, Adriaenssens T, Van den Branden BJ, Henriques JP, Van der Schaaf RJ, Koolen JJ, Vermeersch PH, Bosschaert MA, Tijssen JG, Suttorp MJ.

Trials. 2012 Dec 15;13:240. doi: 10.1186/1745-6215-13-240.

41.

The impact of multivessel disease with and without a co-existing chronic total occlusion on short- and long-term mortality in ST-elevation myocardial infarction patients with and without cardiogenic shock.

Hoebers LP, Vis MM, Claessen BE, van der Schaaf RJ, Kikkert WJ, Baan J Jr, de Winter RJ, Piek JJ, Tijssen JG, Dangas GD, Henriques JP.

Eur J Heart Fail. 2013 Apr;15(4):425-32. doi: 10.1093/eurjhf/hfs182. Epub 2012 Nov 12.

42.

Radiation exposure during percutaneous coronary interventions and coronary angiograms performed by the radial compared with the femoral route.

Kuipers G, Delewi R, Velders XL, Vis MM, van der Schaaf RJ, Koch KT, Henriques JP, de Winter RJ, Baan J Jr, Tijssen JG, Piek JJ.

JACC Cardiovasc Interv. 2012 Jul;5(7):752-7. doi: 10.1016/j.jcin.2012.03.020.

43.

Routine use of the transradial approach in primary percutaneous coronary intervention: procedural aspects and outcomes in 2209 patients treated in a single high-volume centre.

Vink MA, Amoroso G, Dirksen MT, van der Schaaf RJ, Patterson MS, Tijssen JG, Kiemeneij F, Slagboom T.

Heart. 2011 Dec;97(23):1938-42. doi: 10.1136/heartjnl-2011-300524. Epub 2011 Aug 31.

PMID:
21880651
44.

Patency of paclitaxel-eluting versus bare metal stents long term after implantation in acute ST-segment elevation myocardial infarction.

Vink MA, Van Nooijen FC, Laarman GJ, Suttorp MJ, Tijssen JG, Slagboom T, Patterson MS, Van Der Schaaf RJ, Kiemeneij F, Amoroso G, Dirksen MT.

Am J Cardiol. 2011 Nov 1;108(9):1214-9. doi: 10.1016/j.amjcard.2011.06.034. Epub 2011 Aug 23.

PMID:
21864813
45.

Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis.

van der Laan AM, Schirmer SH, de Vries MR, Koning JJ, Volger OL, Fledderus JO, Bastiaansen AJ, Hollander MR, Baggen JM, Koch KT, Baan J Jr, Henriques JP, van der Schaaf RJ, Vis MM, Mebius RE, van der Pouw Kraan TC, Quax PH, Piek JJ, Horrevoets AJ, van Royen N.

Eur Heart J. 2012 May;33(9):1076-84. doi: 10.1093/eurheartj/ehr220. Epub 2011 Aug 10.

PMID:
21831908
46.

The effect of repeated ischaemic periods on left ventricular dynamics during percutaneous coronary intervention.

Remmelink M, de Winter RJ, Henriques JP, Koch KT, van der Schaaf RJ, Vis MM, Tijssen JG, Piek JJ, Baan J Jr.

EuroIntervention. 2010 Nov;6(5):623-9. doi: 10.4244/EIJV6I5A104.

PMID:
21044917
47.

Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction.

Claessen BE, Hoebers LP, van der Schaaf RJ, Kikkert WJ, Engstrom AE, Vis MM, Baan J Jr, Koch KT, Meuwissen M, van Royen N, de Winter RJ, Tijssen JG, Piek JJ, Henriques JP.

Heart. 2010 Dec;96(24):1968-72. doi: 10.1136/hrt.2010.197673. Epub 2010 Oct 7.

PMID:
20930044
48.

Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.

van der Schaaf RJ, Claessen BE, Hoebers LP, Verouden NJ, Koolen JJ, Suttorp MJ, Barbato E, Bax M, Strauss BH, Olivecrona GK, Tuseth V, Glogar D, Råmunddal T, Tijssen JG, Piek JJ, Henriques JP; EXPLORE investigators.

Trials. 2010 Sep 21;11:89. doi: 10.1186/1745-6215-11-89.

49.

ST-segment resolution prior to primary percutaneous coronary intervention is a poor indicator of coronary artery patency in patients with acute myocardial infarction.

Verouden NJ, Haeck JD, Koch KT, Henriques JP, Baan J, van der Schaaf RJ, Vis MM, Peters RJ, Wilde AA, Piek JJ, Tijssen JG, de Winter RJ.

Ann Noninvasive Electrocardiol. 2010 Apr;15(2):107-15. doi: 10.1111/j.1542-474X.2010.00350.x.

PMID:
20522050
50.

Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock.

van der Schaaf RJ, Claessen BE, Vis MM, Hoebers LP, Koch KT, Baan J Jr, Meuwissen M, Engstrom AE, Kikkert WJ, Tijssen JG, de Winter RJ, Piek JJ, Henriques JP.

Am J Cardiol. 2010 Apr 1;105(7):955-9. doi: 10.1016/j.amjcard.2009.11.014. Epub 2010 Feb 13.

PMID:
20346312

Supplemental Content

Loading ...
Support Center